Camurus AB (publ) CAMRF
71.90 USD 0.00 (+0.00%)
At closeNov 10, 2026, 4:00 PM EST
71.90 Day range 71.90
54.00 52-week range 71.90
- YTD
- +7.11%
- 1 year
- +25.15%
News
seekingalpha.com Camurus AB (publ) (CAMRF) Q3 2026 Earnings Call Transcript Camurus AB (publ) (CAMRF) Q3 2026 Earnings Call Transcript
prnewswire.com Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA PDUFA target action date set to 18 December 2026 LUND, Sweden, July 17, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted for…
seekingalpha.com Camurus AB (publ) (CAMRF) Q2 2026 Earnings Call Transcript Camurus AB (publ) (CAMRF) Q2 2026 Earnings Call Transcript
reuters.com Camurus' hormone disorder drug expected to be approved in 2027 after fresh FDA setback Wall Street has pushed to next year expectations for a U.S. approval for Camurus' drug to treat a rare hormonal condition after the health regulator's second refusal on Wednesday.
prnewswire.com Camurus announces expansion of Lilly collaboration LUND, Sweden, June 1, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the…
seekingalpha.com Camurus AB (publ) (CAMRF) Q1 2026 Earnings Call Transcript Camurus AB (publ) (CAMRF) Q1 2026 Earnings Call Transcript
seekingalpha.com Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript Camurus AB (publ) (CAMRF) Q4 2025 Earnings Call Transcript
seekingalpha.com Camurus AB (publ) (CAMRF) Q3 2025 Earnings Call Transcript Camurus AB (publ) (OTCPK:CAMRF) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Fredrik Tiberg - President, CEO, CSO & Director Anders Vadsholt - Chief Financial Officer…
prnewswire.com Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly's proprietary drug compounds Camurus eligible to receive up to $870 million in…
reuters.com US FDA declines to approve Camurus' rare hormone disorder drug The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish…
prnewswire.com New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl LUND, Sweden , June 25, 2024 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase…
benzinga.com Stocks That Hit 52-Week Highs On Friday